NCT02227199View on ClinicalTrials.gov

Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 10, 2014

Primary Completion Date

March 30, 2020

Study Completion Date

September 30, 2025

Conditions
Recurrent Hodgkin LymphomaRefractory Hodgkin Lymphoma
Interventions
DRUG

Brentuximab Vedotin

Given IV

DRUG

Carboplatin

Given IV

DRUG

Etoposide

Given IV

DRUG

Ifosfamide

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Seagen Inc.

INDUSTRY

lead

University of Washington

OTHER

NCT02227199 - Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter